The novel allosteric BCR::ABL1 inhibitor asciminib was developed to treat CML patients alone or in combination to overcome or potentially prevent these treatment-emergent TKD mutations. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.